Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Current Assets (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Current Assets for 8 consecutive years, with $677.4 million as the latest value for Q1 2026.

  • For Q1 2026, Current Assets rose 35.23% year-over-year to $677.4 million; the TTM value through Mar 2026 reached $677.4 million, up 35.23%, while the annual FY2025 figure was $871.2 million, 70.74% up from the prior year.
  • Current Assets hit $677.4 million in Q1 2026 for Kymera Therapeutics, down from $871.2 million in the prior quarter.
  • Across five years, Current Assets topped out at $871.2 million in Q4 2025 and bottomed at $375.7 million in Q3 2023.
  • Average Current Assets over 5 years is $516.1 million, with a median of $501.0 million recorded in 2025.
  • Year-over-year, Current Assets dropped 23.95% in 2023 and then soared 70.74% in 2025.
  • Kymera Therapeutics' Current Assets stood at $419.4 million in 2022, then fell by 3.36% to $405.3 million in 2023, then rose by 25.89% to $510.3 million in 2024, then skyrocketed by 70.74% to $871.2 million in 2025, then dropped by 22.24% to $677.4 million in 2026.
  • According to Business Quant data, Current Assets over the past three periods came in at $677.4 million, $871.2 million, and $528.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.